Grants and Contributions

To be eligible to the competition, the application must address ALL objectives; the specific objectives of this funding opportunity are to:

• Include a large and robust serosurveillance study of children and youth that can inform research to understand the current state of natural and vaccine-based immunity in this population, and measures to best protect this vulnerable population in Canada;
• Harmonize data collection, and improve open and real-world data sharing with relevant knowledge-users in an accessible, useful and relevant format to support a timely and effective COVID-19 public health response within and across all jurisdictions in Canada as it relates to children and youth;
• Collaborate across Sites to establish resource and data sharing policies, increase efficiencies in research and related processes (including but not limited to ethics review; privacy considerations; contracts; informed-consent; common protocols; developing applications for trial funding; and consistent and valid patient-oriented outcomes), reduce duplication, and maximize research and surveillance activities related to COVID-19 infection and/or vaccination consequences of children and youth;
• Generate research evidence related to COVID-19 infection in diverse children and youth populations, including (but not limited to):
o Equity considerations;
o Health and wellness status (e.g., historically excluded or underserved populations, individuals with complex health needs and/or a disability);
o Sex and gender; and/or
o Racialized and Indigenous (First Nations, Inuit, Métis and Urban Indigenous Peoples) populations; and
• Provide research evidence to inform clinical and health system management and public health response, and/or decision-making and planning within and across jurisdictions in Canada and internationally.

Support provided to the International Society for Vaccines, the world's largest non-commercial, scientific conference for basic and clinical researchers interested in vaccines and underlying sciences.

To develop and improve technology to promote a safer road transportation system To support education and training to improve the safety of roadways road users and motor vehicles

To address the challenges of SARS2 COVID-19 pandemic, messenger ribonucleic acid (mRNA) vaccines were developed. While mRNA vaccines and other RNA therapeutics are powerful tools in combatting diseases, their shelf-life is dependent on the integrity of cold chain logistics - the necessity of always storing the vaccine between 4?

The specific objectives of this funding opportunity are to continue to:
• Provide central coordination and lead collaboration activities with clinical trials groups/networks in a transparent and inclusive manner to increase the availability of high-quality and real-time clinical trial evidence to prevent, diagnose, and/or treat COVID-19 (e.g., through clinical trials of vaccines, therapeutics, or diagnostic tests);
• Collaborate across member networks to expand resource and data sharing policies, including creating data sharing agreements and increasing efficiencies in research and related processes (including, but not limited to ethics review; contracts; common protocols; developing applications for trial funding; consistent and valid patient-oriented outcomes), reduce duplication, and maximize research impact for COVID-19;
• Enhance local, national and/or international clinical trial collaborative efforts by aligning clinical trials networks with other COVID-19 research investments to prevent and/or mitigate the rapid spread of COVID-19 and related negative consequences; and
• Engage stakeholders in research prioritization and oversight, provide evidence to inform clinical/ health system management and public health responses, and/or decision-making and planning within and across jurisdictions in Canada and internationally.

These can include: communities marginalized by race; First Nations, Inuit, Métis and Urban Indigenous Peoples; communities historically excluded from research; those experiencing health inequities; persons with disabilities and individuals across diverse health status (e.g. vaccination status, high risk populations, individuals with comorbid conditions); those experiencing gendered impacts of the pandemic; and those in life stages that have been underrepresented in research.

These can include: communities marginalized by race; First Nations, Inuit, Métis and Urban Indigenous Peoples; communities historically excluded from research; those experiencing health inequities; persons with disabilities and individuals across diverse health status (e.g. vaccination status, high risk populations, individuals with comorbid conditions); those experiencing gendered impacts of the pandemic; and those in life stages that have been underrepresented in research.

Development of a neutralizing antibody detection kit to accelerate the development of vaccines and immunotherapies.

During the recent Covid-19 pandemic, some novel lipid molecules became the key ingredient in developing mRNA and DNA-based vaccines against Covid-19 (SARS-CoV-2). There is also an increased interest in expanding the mRNA/DNA-based therapies into developing novel drugs for cancer and other rare diseases.

Through the application of national and local priorities, the CSJ program seeks to provide youth, particularly those who face barriers to employment with access to work opportunities. Funded employers must demonstrate that they are providing quality work experiences for youth that provide opportunities to develop and improve their skills.